<DOC>
	<DOCNO>NCT02674295</DOCNO>
	<brief_summary>The purpose study determine metabolic disposition radiolabeled esketamine administer oral intravenous route healthy male participant .</brief_summary>
	<brief_title>A Mass Balance Study With Microtracer Dose 14C-esketamine Healthy Male Participants</brief_title>
	<detailed_description>This single-center , open-label ( identity study drug know participant study staff ) , single-dose , parallel-group study . The study consist Screening Phase ( Days -21 -2 ) , Open-label treatment Phase ( Day -1 Day 8 ) End Study ( 9 13 day last study assessment ) . The total duration study Screening Phase Follow-up , 37-41 day . Participants assign 1 two group ( Cohort 1 Cohort 2 ) treatment phase . The participant primarily evaluate determine metabolic disposition radiolabeled esketamine administer oral intravenous route . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Participants willing adhere prohibition restriction specify protocol If man sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate investigator ( example , vasectomy , doublebarrier , partner use effective contraception ) 3 month follow administration study drug Participants body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) ( inclusive ) , body weight less 50 kg Blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic . Note : Average 3 supine measurement use screen visit A 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function , include : Sinus rhythm ; Heart rate 45 90 beat per minute ( bpm ) ; QTc interval less equal ( &lt; = ) 450 millisecond ( m ) ; QRS interval &lt; 110 m ; PR interval &lt; 200 m ; Morphology consistent healthy cardiac conduction function Participants diagnose current previous psychiatric bipolar disorder , assess investigator , permit participate study Current suicidal homicidal ideation/intent/behavior assess Columbia Suicide Severity Rating Scale ( CSSRS ) screen Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission study center Day 1 deem appropriate investigator Clinically significant abnormal physical examination , vital sign 12lead ECG screen Day 1 , deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) within 14 day study drug administration schedule , except acetaminophen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-54135419</keyword>
	<keyword>Esketamine</keyword>
</DOC>